Predictive value on advance Hodgkin Lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial

Biggi, Alberto;Chauvie, Stephane;Fallanca, Federico;Guerra, Luca;Bergesio, Fabrizio;Menga, Massimo;Bianchi, Andrea;Gregianin, Michele;Chiaravalloti, Agostino;Schillaci, Orazio;Pavoni, Chiara;Patti, Caterina;Picardi, Marco;Romano, Alessandra;Schiavotto, Corrado;Sorasio, Roberto;Viviani, Simonetta;La Nasa, Giorgio;Trentin, Livio;Rambaldi, Alessandro;Gallamini, Andrea

2023-01-01

---

Abstract

The Lugano classification for response assessment in lymphoma recommends the use of the 5-point-scale Deauville Score (DS) to assess response evaluation of end-of-treatment FDG-PET/CT (eotPET) in Hodgkin Lymphoma (HL); nevertheless, there is a paucity of data on its accuracy and reproducibility. We focus here on the cohort of advanced stage IIb-IV HL patients enrolled in the HD0607 clinical trial (NCT identifier 00795613) that having had a negative interim PET performed 6 cycles of ABVD (Doxorubicin, Vinblastine, Vincristine and Dacarbazine) and then performed an eotPET. Negative patients were randomized to radiotherapy and no further treatment while positive patients were treated based on local policies. eotPET was re-evaluated independently by two readers evaluated and progression free survival was analysed (PFS). eotPET of 254 patients were analysed. The median follow-up was 43 months. The best receiver operator characteristics cut-off values to distinguish positive and negative patients was 4. The area-under-the-curve was 0.81 (95%CI, 0.70–0.91). Three-years PFS was 0.95 (95% CI 0.90–0.97) in eotPET negative and 0.22 (95% CI 0.11–0.43) in eotPET positive. DS demonstrated a good reproducibility of positivity/negativity between the readers consensus and local site evaluation where the agreement occurred on 95.0% of patients. The present study demonstrates that eotPET is an accurate tool to predict treatment outcome in HL and confirms the appropriateness of the Lugano classification for eotPET evaluation.